NCT07469956 2026-03-13Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic CancerSun Yat-sen UniversityPhase 2 Not yet recruiting30 enrolled
NCT06531291 2024-07-31Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine DifferentiationRenJi HospitalPhase 2 Not yet recruiting80 enrolled